cinnamylsulphonylpropionic acid

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: cinnamylsulphonylpropionic acid
• 英文别名: 2-[(E)-3-phenylprop-2-enyl]sulfonylpropanoic acid
• 化学式: C₁₂H₁₄O₄S
• 分子量: 254.307
• InChiKey: CHCRDBGXXPSVQZ-VMPITWQZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  17
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  79.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  cinnamylsulphonylpropionic acid 、 硫代乳酸 、 Cinnamyl bromide 生成 cinnamylthiopropionic acid
  参考文献：
  名称：

  SRS-A antagonists

  摘要：

  描述了在涉及SRS-A作为因果介质的过敏/炎症性疾病治疗中有用的药理活性化合物，这些化合物在游离酸形式下的化学式为I，其中R.sub.1是(i)具有多达20个碳原子的脂肪烃基、饱和或不饱和的烃基，未取代或被至少一种取代基取代，所述取代基选自卤素、羟基、C.sub.3-6烷氧基、C.sub.3-6环烷基、芳基或杂环芳基，所述环烷基、芳基或杂环芳基未取代或被至少一种取代基取代，所述取代基选自羟基、卤素和多达10个碳原子的烷基、烯基或炔基，(ii)具有3至8个碳原子的未取代或被多达16个碳原子的烷基、烯基或炔基取代的环烷基，或(iii)芳基或杂环芳基，未取代或被羟基、C.sub.1-4烷氧基、卤素或多达16个碳原子的烷基、烯基或炔基取代；R.sub.2是(i)多达10个碳原子的烷基、环烷基或烯基，未取代或被一个或多个取代基取代，所述取代基选自芳基、环烷基、卤素、羟基、NHR.sub.3和COX，其中R.sub.3为H、C.sub.1-4烷基、芳基或氨基酸残基或COX，X为OH、C.sub.1-4烷基、NH.sub.2或氨基酸残基，或(ii)芳基或杂环芳基，未取代或被一个或多个取代基取代，所述取代基选自C.sub.1-4烷基、C.sub.1-4烷氧基、C.sub.2-5酰基、卤素、羟基、羧基、硝基、三卤甲基、苯基、C.sub.1-4酰胺基和NHR.sub.4，其中R.sub.4为氢或C.sub.1-4烷基；Y为--S--、--SO--或--SO.sub.2--，但当--YR.sub.2为谱胱甘肽、半胱氨酸或半胱氨酰甘氨酸时，R.sub.1不是12至16个碳原子的未取代的α-四烯基或α-五烯基基团。

  公开号：

  US04513005A1

文献信息

• Sulphur-containing 5-hydroxy-alkanoic acid derivatives, their use as pharmaceutical preparations and process for their production
  申请人：Lilly Industries Limited

  公开号：EP0068739A1

  公开（公告）日：1983-01-05

  There are described pharmacologically active compounds, useful in the treatment of allergic/inflammatory disorders involving SRS-A as causal mediator and which, in free acid form, are of formula I, in which R1 is (i) an aliphatic, saturated or unsaturated hydrocarbyl radical of up to 20 carbon atoms, unsubstituted or substituted by at least one substituent selected from halogen, hydroxy, C3-6 alkoxy, C3-6 cycloalkyl, aryl or heteroaryl, the cycloalkyl, aryl or heteroaryl being unsubstituted or substituted by at least one substituent selected from hydroxy, halogen and alkyl, alkenyl or alkynyl of up to 10 carbon atoms, (ii) cycloalkyl of 3 to 8 carbon atoms unsubstituted or substituted by alkyl, alkenyl or alkynyl of up to 16 carbon atoms, or (iii) aryl or heteroaryl, unsubstituted or substituted by hydroxyl, C1-4 alkoxy, halogen or alkyl, alkenyl or alkynyl of up to 16 carbon atoms; and R2 is (i) alkyl, cycloalkyl or alkenyl of up to 10 carbon atoms, unsubstituted or substituted by one or more substituents selected from aryl, cycloalkyl, halogen, hydroxy, NHR3 and COX, where R3 is H, C1-4 alkyl, aryl or an amino acid residue or COX, and X is OH, C1-4 alkyl, NH2 or an amino acid residue, or (ii) aryl or heteroaryl, unsubstituted or substituted by one or more substituents selected from C1-4 alkyl, C1-4 alkoxy, C2-5 acyl, halogen, hydroxy, carboxy, nitro, trihalomethyl, phenyl, C1-4 acylamino and NHR4, where R4 is hydrogen or C1-4 alkyl; and Y is -S-, -SO- or -S02-, with the proviso that when -YR2 is glutathionyl, cysteinyl or cysteinylglycinyl, then R1 is other than an unsubstituted alkatetraenyl or alkapentaenyl radical of 12 to 16 carbon atoms.

  所述化合物具有药理活性，可用于治疗以 SRS-A 为病因介质的过敏性/炎症性疾病，其游离酸形式如式 I 所示、 其中 R1 是 (i) 脂肪族、饱和或不饱和烃基，碳原子数不超过 20 个，未被取代或被至少一个选自卤素、羟基、C3-6 烷氧基、C3-6 环烷基、芳基或杂芳基的取代基取代，环烷基、芳基或杂芳基未被取代或被至少一个选自羟基、卤素和碳原子数不超过 10 个的烷基、烯基或炔基的取代基取代、 (ii) 未被或被不超过 16 个碳原子的烷基、烯基或炔基取代的 3 至 8 个碳原子的环烷基，或 (iii) 芳基或杂芳基，未被或被羟基、C1-4 烷氧基、卤素或最多 16 个碳原子的烷基、烯基或炔基取代； 而 R2 是 (i) 碳原子数不超过 10 的烷基、环烷基或烯基，未被取代或被选自芳基、环烷基、卤素、羟基、NHR3 和 COX 的一个或多个取代基取代，其中 R3 是 H、C1-4 烷基、芳基或氨基酸残基或 COX，X 是 OH、C1-4 烷基、NH2 或氨基酸残基、NH2 或氨基酸残基，或 (ii) 芳基或杂芳基，未被取代或被一个或多个选自 C1-4 烷基、C1-4 烷氧基、C2-5 乙酰基、卤素、羟基、羧基、硝基、三卤甲基、苯基、C1-4 乙酰氨基和 NHR4 的取代基取代，其中 R4 是氢或 C1-4 烷基；Y为-S-、-SO-或-S02-、 但当-YR2 为谷胱甘肽基、半胱氨酸基或半胱氨酰甘氨酰时，R1 不是 12 至 16 个碳原子的未取代烷四烯基或烷五烯基。
• US4513005A
  申请人：——

  公开号：US4513005A

  公开（公告）日：1985-04-23
• SRS-A antagonists
  申请人：Lilly Industries Limited

  公开号：US04513005A1

  公开（公告）日：1985-04-23

  There are described pharmacologically active compounds, useful in the treatment of allergic/inflammatory disorders involving SRS-A as causal mediator and which, in free acid form, are of formula I, ##STR1## in which R.sub.1 is (i) an aliphatic, saturated or unsaturated hydrocarbyl radical of up to 20 carbon atoms, unsubstituted or substituted by at least one substituent selected from halogen, hydroxy, C.sub.3-6 alkoxy, C.sub.3-6 cycloalkyl, aryl or heteroaryl, the cycloalkyl, aryl or heteroaryl being unsubstituted or substituted by at least one substituent selected from hydroxy, halogen and alkyl, alkenyl or alkynyl of up to 10 carbon atoms, (ii) cycloalkyl of 3 to 8 carbon atoms unsubstituted or substituted by alkyl, alkenyl or alkynyl of up to 16 carbon atoms, or (iii) aryl or heteroaryl, unsubstituted or substituted by hydroxyl, C.sub.1-4 alkoxy, halogen or alkyl, alkenyl or alkynyl of up to 16 carbon atoms; and R.sub.2 is (i) alkyl, cycloalkyl or alkenyl of up to 10 carbon atoms, unsubstituted or substituted by one or more substituents selected from aryl, cycloalkyl, halogen, hydroxy, NHR.sub.3 and COX, where R.sub.3 is H, C.sub.1-4 alkyl, aryl or an amino acid residue or COX, and X is OH, C.sub.1-4 alkyl, NH.sub.2 or an amino acid residue, or (ii) aryl or heteroaryl, unsubstituted or substituted by one or more substituents selected from C.sub.1-4 alkyl, C.sub.1-4 alkoxy, C.sub.2-5 acyl, halogen, hydroxy, carboxy, nitro, trihalomethyl, phenyl, C.sub.1-4 acylamino and NHR.sub.4, where R.sub.4 is hydrogen or C.sub.1-4 alkyl; and Y is --S--, --SO-- or --SO.sub.2 --, with the proviso that when --YR.sub.2 is glutathionyl, cysteinyl or cysteinylglycinyl, then R.sub.1 is other than an unsubstituted alkatetraenyl or alkapentaenyl radical of 12 to 16 carbon atoms.

  描述了在涉及SRS-A作为因果介质的过敏/炎症性疾病治疗中有用的药理活性化合物，这些化合物在游离酸形式下的化学式为I，其中R.sub.1是(i)具有多达20个碳原子的脂肪烃基、饱和或不饱和的烃基，未取代或被至少一种取代基取代，所述取代基选自卤素、羟基、C.sub.3-6烷氧基、C.sub.3-6环烷基、芳基或杂环芳基，所述环烷基、芳基或杂环芳基未取代或被至少一种取代基取代，所述取代基选自羟基、卤素和多达10个碳原子的烷基、烯基或炔基，(ii)具有3至8个碳原子的未取代或被多达16个碳原子的烷基、烯基或炔基取代的环烷基，或(iii)芳基或杂环芳基，未取代或被羟基、C.sub.1-4烷氧基、卤素或多达16个碳原子的烷基、烯基或炔基取代；R.sub.2是(i)多达10个碳原子的烷基、环烷基或烯基，未取代或被一个或多个取代基取代，所述取代基选自芳基、环烷基、卤素、羟基、NHR.sub.3和COX，其中R.sub.3为H、C.sub.1-4烷基、芳基或氨基酸残基或COX，X为OH、C.sub.1-4烷基、NH.sub.2或氨基酸残基，或(ii)芳基或杂环芳基，未取代或被一个或多个取代基取代，所述取代基选自C.sub.1-4烷基、C.sub.1-4烷氧基、C.sub.2-5酰基、卤素、羟基、羧基、硝基、三卤甲基、苯基、C.sub.1-4酰胺基和NHR.sub.4，其中R.sub.4为氢或C.sub.1-4烷基；Y为--S--、--SO--或--SO.sub.2--，但当--YR.sub.2为谱胱甘肽、半胱氨酸或半胱氨酰甘氨酸时，R.sub.1不是12至16个碳原子的未取代的α-四烯基或α-五烯基基团。